ArticleActa diabetologica2023
The association of homocysteine level with the risk of diabetic nephropathy and diabetic retinopathy in NHANES.
Article in Acta diabetologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Homocysteine and mitophagy in diabetic retinopathy: unraveling the underlying molecular crosstalk.Endocrine · 2026Review
- LncPTEC mediated homocysteine accumulation elevates oxidative stress via UBQLN1-dependent MTHFD1 ubiquitination in DKD.Cell death & disease · 2026Article
- Development and validation of a multi-center nomogram for the presence of diabetic retinopathy in patients with type 2 diabetes: incorporating homocysteine, glycemic, lipid, and renal markers.Frontiers in endocrinology · 2026Article
- The MTHFR C677T genetic susceptibility and its role in risk prediction for type 2 diabetic nephropathy in Northern China.Frontiers in endocrinology · 2026Article
- MTHFR C677T polymorphism and T2DM risk in Iraqi Kurds: a cross-sectional study.Annals of medicine and surgery (2012) · 2025Article
- Correlation between renal function and OCTA parameters of the retina and choroid in early-stage diabetic patients.Journal of translational medicine · 2025Article
- Hyperhomocysteinemia: A Predictor of Microvascular Complications in Type 2 Diabetes Mellitus.Cureus · 2025Article
- A retrospective cohort study of H-type hypertension and its influence on the prognostic effect in patients with non-dialysis CKD.Frontiers in nutrition · 2025Article
- Machine learning model for age related macular degeneration based on pesticides: the National Health and Nutrition Examination Survey 2007-2008.Frontiers in public health · 2025Article
- Molecular-Genetic Biomarkers of Diabetic Macular Edema.Journal of clinical medicine · 2024Review
- The Potential of Mesenchymal Stem/Stromal Cells in Diabetic Wounds and Future Directions for Research and Therapy-Is It Time for Use in Everyday Practice?International journal of molecular sciences · 2024Review
- The impact of SLCO1B1 polymorphisms on homocysteine concentrations: evidence for a stronger association in men.Frontiers in nephrology · 2024Article
- Effect of plasma homocysteine on cardiometabolic multimorbidity among Chinese adults: a population-based and real-world evidence study.Frontiers in nutrition · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
aimsTo examine the association of homocysteine (Hcy) with diabetic nephropathy (DN) and diabetic retinopathy (DR) in a representative United States population.
methodsThis was a cross-sectional study using data from participants in the National Health and Nutrition Examination Survey 2005-2006. Metrics including Hcy level, urinary albumin to creatinine ratio, estimated glomerular filtration rate, and retinopathy grading were collected. Multiple logistic regression models were employed to assess the association of Hcy with DN and DR.
results630 participants were included in this study. The Hcy level was significantly higher in those with DN and DR than those without DN and DR. Hcy was associated with an increased risk of DN (OR = 1.31, 95% CI 1.18-1.46; P < 0.001). In the fully adjusted model of DN (model II), compared to participants in quartiles 1 of Hcy, the adjusted ORs for participants in quartiles 2-4 were 1.49 (95% CI 0.52-4.26; P = 0.426), 3.81 (95% CI 1.35-10.73; P = 0.015), and 14.08 (95% CI 3.84-51.66; P = 0.001), respectively. Hcy was also associated with an increased risk of DR (OR = 2.260, 95% CI 1.212-4.216; P = 0.014), but this association was non-significant in the fully adjusted model of DR (model II).
conclusionsIn diabetic patients, Hcy was associated with increased risk of DN in a non-linear manner. In addition, Hcy was associated with the risk of DR, but the association was attenuated after adjusting for confounders. In the future, Hcy can potentially be used as an early screening indicator for diabetic microvascular complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.